je.st
news
Trevena Announces Positive Results From Phase 2b Study Of TRV130 In Acute Postoperative Pain
2015-09-02 07:04:14| drugdiscoveryonline News Articles
Trevena, Inc., a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors (GPCRs), recently announced positive data from its randomized, double-blind, placebo- and active-controlled Phase 2b trial of TRV130 in moderate to severe acute postoperative pain after abdominoplasty surgery
Tags: results
study
positive
phase
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||